CTKB
Cytek Biosciences, Inc.Company Information
- Company Name
- Cytek Biosciences, Inc.
- CIK
- CIK0001831915
- Category
- Accelerated filer
- Ticker: Exchange
- CTKB: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 08 Industrial Applications and Services
- SIC
- 3826
- SIC Description
- Laboratory Analytical Instruments
- Ticker
- CTKB
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-06-02
- Last sale
- 2024-04-19
- Shares purchased (TTM)
- 35,000
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 79,142,605
- Shares outstanding
- 129,460,518
- Ownership
- 61.13%
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- 11.96%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 74 | 66 | 91 | 93 | 75 | 95 | 99 | 162 | 178 | 169 | 167 | 164 | ||||||
| Restricted Cash Current | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Marketable Securities | 188 | 197 | 171 | 168 | 187 | 170 | 179 | 116 | 99 | 101 | 95 | 124 | ||||||
| Accounts Receivable Net Current | 50 | 52 | 63 | 57 | 56 | 55 | 61 | 53 | 45 | 50 | 56 | 55 | ||||||
| Inventory Net | 52 | 50 | 48 | 52 | 49 | 45 | 44 | 47 | 50 | 55 | 61 | 67 | ||||||
| Prepaid Expense And Other Assets Current | 14 | 15 | 20 | 18 | 15 | 15 | 14 | 13 | 12 | 13 | 13 | 12 | ||||||
| Assets Current | 378 | 379 | 392 | 388 | 383 | 381 | 396 | 390 | 384 | 389 | 392 | 422 | ||||||
| Deferred Tax Assets Deferred Income | - | - | 0 | 38 | 36 | 34 | 33 | 31 | 30 | 33 | 30 | 24 | ||||||
| Property Plant And Equipment Net | 21 | 20 | 18 | 18 | 18 | 18 | 18 | 19 | 18 | 18 | 18 | 17 | ||||||
| Operating Lease Right Of Use Asset | 11 | 11 | 11 | 11 | 16 | 10 | 10 | 10 | 9 | 10 | 11 | 12 | ||||||
| Goodwill | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 16 | 16 | 16 | 16 | 16 | ||||||
| Intangible Assets Net Excluding Goodwill | 15 | 16 | 17 | 18 | 19 | 19 | 20 | 20 | 21 | 22 | 23 | 24 | ||||||
| Other Assets Noncurrent | 6 | 6 | 7 | 4 | 5 | 5 | 5 | 5 | 5 | 4 | 3 | 3 | ||||||
| Assets | 447 | 449 | 462 | 495 | 493 | 483 | 500 | 491 | 484 | 492 | 494 | 519 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Trade Current | 8 | 7 | 6 | 8 | 7 | 6 | 6 | 5 | 3 | 4 | 3 | 5 | ||||||
| Settlement Liabilities Current | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | ||||||
| Accrued Liabilities Current | 24 | 20 | 23 | 20 | 22 | 19 | 21 | 21 | 15 | 18 | 20 | 21 | ||||||
| Other Liabilities Current | 21 | 22 | 17 | 16 | 15 | 13 | 13 | 9 | 7 | 8 | 8 | 8 | ||||||
| Deferred Revenue Current | 29 | 30 | 29 | 29 | 28 | 28 | 25 | 25 | 24 | 23 | 23 | 23 | ||||||
| Liabilities Current | 84 | 81 | 78 | 75 | 73 | 68 | 68 | 63 | 52 | 56 | 56 | 59 | ||||||
| Litigation Reserve Noncurrent | 6 | 7 | 7 | 8 | 8 | 9 | 9 | 17 | 17 | 17 | 16 | 16 | ||||||
| Deferred Revenue Noncurrent | 18 | 18 | 18 | 16 | 17 | 16 | 16 | 15 | 14 | 15 | 15 | 15 | ||||||
| Operating Lease Liability Noncurrent | 14 | 13 | 14 | 13 | 14 | 7 | 8 | 8 | 8 | 9 | 9 | 10 | ||||||
| Debt Instrument Carrying Amount | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | ||||||
| Other Liabilities Noncurrent | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Liabilities | 125 | 121 | 120 | 116 | 116 | 103 | 104 | 106 | 95 | 99 | 101 | 104 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 452 | 446 | 441 | 435 | 430 | 427 | 431 | 430 | 435 | 429 | 423 | 452 | ||||||
| Retained Earnings Accumulated Deficit | -133 | -121 | -102 | -58 | -52 | -47 | -35 | -45 | -46 | -35 | -29 | -35 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 3 | 2 | 2 | 1 | -0 | -1 | 0 | 0 | -0 | -2 | -1 | -2 | ||||||
| Stockholders Equity | 322 | 328 | 342 | 379 | 378 | 380 | 396 | 385 | 389 | 393 | 393 | 416 | ||||||
| Liabilities And Stockholders Equity | 447 | 449 | 462 | 495 | 493 | 483 | 500 | 491 | 484 | 492 | 494 | 519 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | ||||||
| Common Stock Shares Issued | 130 | 129 | 129 | 128 | 127 | 128 | 129 | 130 | 132 | 131 | 131 | 136 | ||||||
| Shares Outstanding | 130 | 129 | 129 | 128 | 127 | 128 | 129 | 130 | 132 | 131 | 131 | 136 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCytek Biosciences, Inc. (CTKB) — SEC Financial Statements & Analysis
Cytek Biosciences, Inc. (CTKB) is a laboratory analytical instruments company, incorporated in DE. Cytek Biosciences, Inc. trades on Nasdaq as: CTKB. Cytek Biosciences, Inc. (CTKB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, Cytek Biosciences, Inc. carries a market cap of $573.51M, a P/E ratio of -7.12x, a P/B ratio of 1.78x, a P/S ratio of 2.77x, an enterprise value of $499.66M, and an EV/EBITDA multiple of -13.52x. On profitability, it posts a gross margin of 53.23%, an operating margin of -21.60%, a net margin of -38.98%, a Return on Equity (ROE) of -23.04%, a Return on Assets (ROA) of -17.14%, and a Return on Invested Capital (ROIC) of -16.00%. Per share, it reports EPS of $-0.62, diluted EPS of $-0.62, free cash flow per share of $-0.09, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 5.44% year-over-year, net income growth of 1158.64% year-over-year, and EPS growth of 1134.08% year-over-year. On the balance sheet, it maintains a current ratio of 4.48x, a quick ratio of 3.70x, working capital of $293.60M, a debt-to-equity ratio of 0.39x, a debt ratio of 0.28, an interest coverage ratio of -25.34x, free cash flow of $-12.08M (TTM), and net debt of $-73.85M. Figures sourced from SEC EDGAR.
- Market Cap
- $573.51M
- P/E TTM
- -7.12x
- EPS TTM
- $-0.62
- P/B TTM
- 1.78x
- ROE TTM
- -23.04%
- ROA TTM
- -17.14%
- Debt To Equity
- 0.39x
- Free Cash Flow TTM
- $-12.08M
- Net Revenue TTM Growth 1Y
- 5.44%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Cytek Biosciences, Inc. in?
Cytek Biosciences, Inc. (CTKB) operates in the Laboratory Analytical Instruments industry.
What exchange does CTKB trade on?
Cytek Biosciences, Inc. (CTKB) trades on the Nasdaq.
Where is Cytek Biosciences, Inc. incorporated?
Cytek Biosciences, Inc. is incorporated in DE.
When was Cytek Biosciences, Inc. (CTKB)'s most recent SEC filing?
Cytek Biosciences, Inc. (CTKB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is CTKB's market cap?
Cytek Biosciences, Inc. (CTKB) has a market capitalization of $573.51M as of 2026-06-30.
What is CTKB's EPS (earnings per share)?
Cytek Biosciences, Inc. (CTKB)'s trailing twelve month EPS is $-0.62 as of 2026-06-30.
What is CTKB's ROE (return on equity)?
Cytek Biosciences, Inc. (CTKB)'s trailing twelve month Return on Equity (ROE) is -23.04% as of 2026-06-30.
What is CTKB's ROA (return on assets)?
Cytek Biosciences, Inc. (CTKB)'s trailing twelve month Return on Assets (ROA) is -17.14% as of 2026-06-30.
What is CTKB's ROIC (return on invested capital)?
Cytek Biosciences, Inc. (CTKB)'s trailing twelve month Return on Invested Capital (ROIC) is -16.00% as of 2026-06-30.
What is CTKB's EV/EBITDA?
Cytek Biosciences, Inc. (CTKB)'s trailing twelve month EV/EBITDA is -13.52x as of 2026-06-30.